Literature DB >> 33002675

Neurofibromatosis type 2: A nationwide population-based study focused on survival after meningioma surgery.

Charles Champeaux-Depond1, Joconde Weller2, Matthieu Resche-Rigon3.   

Abstract

BACKGROUND: There is no dedicated study on outcome after meningioma surgery in neurofibromatosis type 2 (NF2) patients.
METHODS: We processed the French Système National des Données de Santé (SNDS) database using an algorithm combining the type of surgical procedure and the International Classification of Diseases to retrieve cases of meningioma operated in NF2 patients between 2007 and 2017. Descriptive and survival analyses were performed.
RESULTS: This nationwide study found 184 patients who were operated on for 315 meningiomas over a 10-year period. 57.6 % were female, median age at first surgery was 40 years IQR[24.8-50.2] and 10.9 % were under 18 years. Cranial convexity (23.4 %) and posterior skull base (16.8 %) were the most common locations. 89.7 % of the tumours were benign and 3.3 % malignant. 16.3 % of the patient received radiotherapy and 13.6 % stereotactic radiosurgery. Median follow-up was 6.3 years, IQR[5.3-7]. At data collection, 28 patients were dead (15.2 %) and median age at death was 41.7 years, IQR [32.7-50.4]. 5 patients died within the year of meningioma surgery. OS rates at 5 and 10 years were: 87.8 %, 95 %CI[82.6-93.3] and 73.2 %, 95 %CI[63.7-84.1] respectively. In univariable Cox regression analysis, Mortality-Related Morbidity Index (MRMI) (HR = 1.57, 95 %CI[1.3-1.9], p < 0.001) Expenditure-Related Morbidity Index (HR1.16, 95 %CI[1.09-1.24], p < 0.001), a malignant meningioma (HR=8.15, 95 %CI[2.78-23.85], p < 0.001), and a diagnosis of deafness or vestibular schwannoma (HR=2.52, 95 %CI[1.02-6.23], p = 0.0447), were associated to the outcome. In multivariable analysis, solely the MRMI and a malignant meningioma remained significant predictors of reduce OS.
CONCLUSION: Using this unique database, we found that outcome of NF2 patients after meningioma surgery is impaired, especially for those with significant co-morbidities and affected by a malignant meningioma.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Database; Meningioma; Neurofibromatosis type 2; SNDS; Survival

Mesh:

Year:  2020        PMID: 33002675     DOI: 10.1016/j.clineuro.2020.106236

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  3 in total

1.  Importance of Population-Based Cancer Risk Information in the Care of Patients With Rare Genetic Disorders.

Authors:  Sharon E Plon
Journal:  J Clin Oncol       Date:  2021-11-18       Impact factor: 44.544

2.  Functional Outcome After Spinal Meningioma Surgery. A Nationwide Population-Based Study.

Authors:  Charles Champeaux-Depond; Nicolas Penet; Joconde Weller; Jean-Charles Le Huec; Vincent Jecko
Journal:  Neurospine       Date:  2022-03-31

3.  Two predominant molecular subtypes of spinal meningioma: thoracic NF2-mutant tumors strongly associated with female sex, and cervical AKT1-mutant tumors originating ventral to the spinal cord.

Authors:  Lingyang Hua; Majd Alkhatib; Dino Podlesek; Leila Günther; Thomas Pinzer; Matthias Meinhardt; Silke Zeugner; Sylvia Herold; Daniel P Cahill; Priscilla K Brastianos; Erik A Williams; Victoria E Clark; Ganesh M Shankar; Hiroaki Wakimoto; Leihao Ren; Jiawei Chen; Ye Gong; Gabriele Schackert; Tareq A Juratli
Journal:  Acta Neuropathol       Date:  2022-08-09       Impact factor: 15.887

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.